Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aeterna Zentaris Bumps BPH Therapy Cetrorelix To Front Of Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

With a projected NDA filing in Q1 2010, firm plans to position the LHRH antagonist’s favorable sexual side effect profile compared to agonists such as top-selling Flomax.

You may also be interested in...



Aeterna Zentaris Projects 2010 Filing, 2011 Launch For BPH Candidate

Canadian biotech accelerates cetrorelix development while boosting cash-burn guidance.

Aeterna Zentaris Projects 2010 Filing, 2011 Launch For BPH Candidate

Canadian biotech accelerates cetrorelix development while boosting cash-burn guidance.

Aeterna Shifts Directions Again; CEO And Senior VP Depart

Interim CEO says Canadian biotech will continue development of prostate cancer drug and seek to divest additional non-core assets.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel